International Journal of Biology Research
ISSN: 2455-6548; Impact Factor: RJIF 5.22
Received: 10-08-2019; Accepted: 12-09-2019
www.biologyjournal.in
Volume 4; Issue 4; October 2019; Page No. 51-53

The analysis of interleukin-1β (il-1β) association between pneumonic patients and control in Rewa region

Sandhya Singh Rathor[1], Dr. Rashmi Arnold[2]
[1] Research Scholar Biotechnology, A.P.S. University, Rewa, Madhya Pradesh, India
[2] Professor of Botany, Govt. Girls P.G. College, Rewa, Madhya Pradesh, India

Abstract
The present paper deals with the analysis of Interleukin-1β (IL-1β) association between pneumonic patients and control in Rewa region. Interleukin-1α (IL-1α) and IL-1β are potent proinflammatory cytokines that are produced by a variety of cells and act on virtually every organ system of the body. This association study was carried out on 240 case and control. 5 ml blood sample of case and control were analyzed by ELISA reader for Interleukin-1β concentration. The statistical analysis of this difference in the average concentration of Interleukurin-1β between both groups were analysed by t-test and the value of T-test was found to be statistically significant at the level of P <0.0001, and t=119.0 with df 998. The value of median was found to be 3.9 pg/ml and 3.7 pg/ml for patient and control group respectively.

Keywords: inflammation, interleukin-1β (il-1β), pneumonia, Elisa

1. Introduction
Pneumonia is associated with inflammation of the pulmonic parenchyma that's caused by infectious agents. The clinical syndrome is characterized by native inflammation of the lung that is mirrored by pulmonic symptoms, like cough, phlegm production, chest pain, and symptom. The general inflammatory response ends up in a diversity of symptoms, like fever or physiological condition like sweats and chills. Chest skiagraph might reveal pulmonic lesions and laboratory results often times show blood diseases and an elevated CRP. Respiratory disorder pneumonia is divided into community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) (Anand and Kollef, 2009, Garau *et al.* 2008, Langer, *et al.* 1989 and Van der Kooi, *et al.* 2010) [1, 4]. Community-acquired pneumonia is one in all the foremost common infectious disease requiring medical aid, and it's the third leading explanation for death worldwide (Fine, *et al.* 1996) [5].

The pathophysiology of pneumonia and immune regulation of the inflammatory response to lung infection are poorly understood, and few of the factors causing extreme disorder or dying have been identified. The inflammatory response additionally initiate via bodies free radicals like homocysteine mediated inflammation expand the severity and stiffness of the tissues. The bacterial infection in lungs activates the immune gadget of which begins defense mechanism against the bacteria and produces multiplied amount of immune cells and immunostimulatory proteins and elements (eg. cytokins and complimentary proteins). Therefore the hematological and immunological profiles of infected folks are changed in compression to wholesome persons (Ewig, *et al.* 2010) [6]. The present find out about in aimed to study what are the components of blood and immune machine altering after pneumonic infection and how a whole lot effect of this infection modifications the hematological and immunological profile of infected persons.

2. Material and Methods
Patient recruitment
Medically certified pneumonic patients were recruited from medicine department (OPD) of Shyam Shah medical college, Rewa, Madhya Pradesh, registered during the year 2017 to 2019. 240 pneumonic patients were recruited for present investigation.

All the recruited patients were Central Indian origin mostly from Rewa, Satna, Sidhi, Singrauli and Shahdol. The diagnosis of pneumonia was based on measurement of ESR and those who suffering with the pneumonia.

Healthy controls
240 randomly selected healthy controls (HC) were enrolled in the study. The control group consisted of medical staff and healthy volunteers from Rewa, Satna, Sidhi, Singrauli and Shahdol as well as individuals residing in central region of India. Hence, control group was drawn from same area with similar environmental and social factors with same mean age and sex ratio.

Sample collection strategy
Approximately 5 ml. of blood sample was collected in 0.5 M EDTA tubes from each pneumonic patient as well as from healthy controls. The clinical profile and other information of case and control subjects were filled in a detailed Proforma.

Quantitative measurement of Interleukin-1β (IL-1β)
Principle
Abcam's Human IL-1β *In vitro* ELISA (Enzyme-Linked Immunosorbent Assay) kit is designed for the quantitative measurement of IL-1β in Human serum, plasma, buffered solutions or cell culture medium. A monoclonal antibody specific for IL-1β has been coated onto the wells of the micro titer strips provided. Samples, including standards of known IL-1β concentrations, control specimens or unknowns are pipetteted into these wells. During the first incubation, the standards or samples and a biotinylated monoclonal antibody specific for IL-1β are simultaneously incubated. After washing, the enzyme Streptavidin- HRP, that binds the biotinylated antibody is added, incubated and washed. A TMB substrate solution is added which acts on the bound enzyme to induce a colored reaction product. The intensity of this colored product is directly proportional to the concentration of IL-1β present in the samples. This kit recognize both endogenous and recombinant Human IL-1β (Langereis, *et al.* 2011) [7].

Assay Procedure
a. Prior to use, mixed all reagents throughly taking care not to create any foam within the vials.
b. Determined the number of microplate strips required to test the desired number of samples, plus appropriate number of wells needed for controls and standards. Removed sufficient microplate strips from the pouch.
c. Added 100 µl of each standard, including blank controls to the appropriate wells.
d. Added 100 µl of sample and 1X Control Solution to the appropriate wells.
e. Added 50 µl of 1X Biotinylated anti-IL-1 β to all wells.
f. Covered and incubate for 3 hours at room temperature (18-25°C).

Removed the cover and washed the plate as follows
1. Aspirate the liquid from each well.
2. Add 300 µl of 1X Wash Buffer into each well Aspirate the liquid from each well.
3. Repeat for a total of 3 washes.
4. Add 100 µl of 1X Streptavidin-HRP solution into all wells, including the blank wells.
5. Recover and incubate at room temperature for 30 minutes.
6. Add 100 µl of Chromogen TMB substrate solution into each well and incubate in the dark for 10-20 minutes at room temperature. Avoid direct exposure to light by wrapping the plate in aluminum foil. A

Incubation time of the substrate solution is usually determined by the microplate reader performances many microplate readers record absorbance only up to 2.0 O.D. The O.D. values of the plate should be monitored and the substrate reaction stopped before positive wells are no longer accurately readable (maximum ~20 minutes). 13.11 Add 100 µl of Stop Reagent into each well. Results must be taken immediately after the addition of Stop Reagent or within one hour, if the microplate is stored at 2-8°C in the dark. Absorbance of each well on a spectrophotometer using 450 nm as the primary wavelength and optionally 620 nm (610 nm to 650 nm is acceptable) as the reference wavelength.

3. Calculations
Calculate the mean absorbance for each set of duplicate standards controls, samples and subtract the average zero standard optical density. Plot the standard curve on log-log graph paper, with standard concentration on the x-axis and absorbance on the y-axis. Draw the best-fit straight line through the standard points.

4. Results
The Clinical profile of the patients and control
The table 1 indicating the characteristics at enrollment in age, residence, and ethnicity Pneumonia and healthy control group. The differences between these both graphs in the given attribute are comparable and statistically non- big to keep two groups similar in all standards without the disease taken for the study.

Table 1: Showing the clinical features of pneumonic patients and control participated in this study.

S.N.	Characteristic	Pneumonic Patients	Healthy control
1.	No. of subjects	240	240
2.	Male female ratio	88:152	98:142
3.	Children: Adult	210:30	198:42
4.	Mean Age (in year)	14.7	17.2
5.	Age range (in year)	1-26	4-38
6.	Mean weight (in Kg)	18.12	20.34

The number of patients and control for every cluster is 240 for study. The male feminine quantitative relation for case and control severally was 88:152 and 98:142. Children: Adult quantitative relation between groups 210:30 and 198:42 was for case and control. The average age of the case was 14.7 years and it had been adjusted to 17.2 for control. Average weight was 18.12 and 20.34 was for case and control, severally.

Interleukin-1β (IL-1β) association between pneumonic patients and control
The serum concentration of the IL-1β of 240 patients and control was measured and the results are presented in table 1. Interleukin-1β concentration was found significantly higher in pneumonic patients than control in this study. The average concentration of Interleukin-1 was 46±3.7pg/ml and 22±1.9 pg/ml for patients and control respectively. The statistical analysis of this difference in the average concentration of Interleukurin-1β between both groups were analysed by t-test and the value of t-test was found to be statistically significant at the level of P <0.0001, and t=119.0 with df 998. The value of median was found to be 3.9 pg/ml and 3.7 pg/ml for patient and control group respectively. The standard error of mean was found 8 pg/ml and 2 pg/ml for patients and control respectively. In the current study, the concentration limit of interleukin-1β was found to be 0.6-1.2 pg/ml in patients and 0.8-1.31 pg/ml in healthy control.

Table 2: Comparison of blood concentration of IL-1β in pneumonic patients to control using t-test (unpaired).

S.N.	Parameters	Pneumonic patients	Healthy controls	t-test P value
1.	Mean ± SD	46 ± 3.7	22 ± 1.9	P<0.0001 *** t=119.0 df=998
2.	Median pg/ml	3.9	3.7	
3.	SEM pg/ml	8	2	
4.	Range pg/ml	0.6-1.2	0.8-1.31	



Fig 1: Comparison of pneumatic blood concentration of IL-1β pneumonia patients to control.

5. Discussion

The role of cytokines and *in*terleukins in host defense against respiratory illness has been examined in several previous studies. It is necessary to emphasize that the role of cytokines -within the innate immunologic response to the tract is completely different in those models wherever different pathogens are used. The overall conclusions which will be drawn from these investigations are that Pro-Inflammatory Cytokines, elicited by bacterial Pneumonia likely impaired bacterial clearance from the respiratory organ compartment. Bacterial infections sometimes result from inhalation of contaminated aerosols from environmental sources. Once the bacteria are within the lungs, they preponderantly infect and multiply inside monocytes and macrophages (Horwitz and Silverstein, 1980) [8]. Mortality rates of up to five hundredth are reportable; illustrating the very fact that bacterium respiratory illness remains a difficult communicable disease (Pedro-Botet *et al.* 1998) [9].

A recent study found that when scrutiny with interferon-receptor-deficient rats, with traditional wild-type rats, their lungs prompted the withdrawal of bacteria genus (Kurata *et al.* 2010) [10]. The results of the present study are the same as those published reports, during which the absence of IL-1β signal was related to a much better voidance of bacteria genus from the respiratory organ compartment.

The role of IL-1β in neutrophil recruitment has been certified by first observations that IL-1α and IL-1β can stimulate neutrophils flow in the lungs after the respiratory administration for neutrophil (Nguyen *et al.* 2008, Mohanty *et al.* 2010 and Vanaudenaerde *et al.* 2011) [11, 13]. Therefore, these data collected with the current results show that endogenous IL-1β can at least interfere with antimicrobial defense in some infections.

6. Conclusion

The interleukins involved in this study are directly or indirectly controlling the inflammatory response IL-1β. In this study pneumonic patients found very high amounts of IL-1β 5.

7. References

1. Anand N, Kollef MH. The alphabet soup of pneumonia: CAP, HAP, HCAP, NHAP, and VAP. Semin Respir Crit Care Med, 2009; 30:3-9.
2. Garau J, Baquero F, Perez-Trallero E, *et al*. Factors impacting on length of stay and mortality of community-acquired pneumonia. Clin Microbiol Infect, 2008; 14:322-29.
3. Langer M, Mosconi P, Cigada M, Mandelli M. Long-term respiratory support and risk of pneumonia in critically ill patients. Intensive Care Unit Group of Infection Control. Am Rev Respir Dis. 1989; 140:302-05.
4. Van der Kooi TI, Mannien J, Wille JC, Van Benthem BH. Prevalence of nosocomial infections in the Netherlands, 2007-2008: results of the first four national studies. J Hosp Infect. 2010; 75:168-72.
5. Fine MJ, Smith MA, Carson CA, *et al*. Prognosis and outcomes of patients with community acquired pneumonia. *A meta-analysis*. JAMA. 1996; 275:134-41.
6. Ewig S, Welte T, Chastre J, Torres A. rethinking the concepts of community-acquired and healthcare-associated pneumonia. Lancet Infect Dis. 2010; 10:279-87.
7. Langereis JD, Oudijk EJ, Schweizer RC, Lammers JW, Koenderman L, *et al*. Steroids induce a disequilibrium of secreted interleukin-1 receptor antagonist and interleukin-1beta synthesis by human neutrophils. The European respiratory journal: official journal of the European Society for Clinical Respiratory Physiology. 2011; 37:406-415.
8. Horwitz MA, Silverstein SC. Legionnaires' disease bacterium (*Legionella pneumophila*) multiples intracellularly in human monocytes. J Clin. Invest. 1980; 66:441-450.
9. Pedro-Botet ML, *et al.* Role of immunosuppression in the evolution of Legionnaires' disease. Clin. Infect. Dis. 1998; 26:14-19.
10. Kurata S, Taguchi H, Sasaki T, Fujioka Y, Kamiya S. Antimicrobial and immunomodulatory effect of clarithromycin on macrolide-resistant Mycoplasma pneumoniae. J Med Microbiol. 2010; 59:693-701.
11. Nguyen CQ, Hu MH, Li Y, Stewart C, Peck AB. Salivary gland tissue expression of interleukin-23 and interleukin-17 in Sjögren's syndrome: findings in humans and mice. Arthritis Rheum. 2008; 58(3):734-743.
12. Mohanty SK, Ivantes CA, Mourya R, Pacheco C, Bezerra JA. Macrophages are targeted by rotavirus in experimental biliary atresia and induce neutrophil chemotaxis by Mip2/Cxcl2. Pediatr Res. 2010; 67(4):345-351.
13. Vanaudenaerde BM, *et al.* Innate and adaptive interleukin-17-producing lymphocytes in chronic inflammatory lung disorders. Am. J Respir. Crit. Care Med. 2011; 183:977-986.
14. Alyavi AL, Sabirjanova ZT, Tulyaganova DK, Radjabova DI, Nuritdinova SK, Khan T. Relationship between cytokines and the remodeling of the structural and functional state of the left ventricle in patients with coronary artery disease.